The results described here show that the benefit from treatment with regorafenib compared with placebo increased to 36% in the STC1-high group (HR = 0.64 for OS), suggesting that the role of STC1 as a potential marker for treatment benefit with regorafenib compared with placebo in refractory colorectal cancer should be further assessed. This evidence concerns the gene STC1 and colorectal cancer.